BC
PCRX icon

Bartlett & Co’s Pacira BioSciences PCRX Stock Holding History

Bartlett & Co’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-32
Closed -$1K – 1078
2022
Q4 		$1K Hold
32
– – ﹤0.01% 1051
2022
Q3 		$2K Hold
32
– – ﹤0.01% 1060
2022
Q2 		$2K Buy
+32
New +$2.1K ﹤0.01% 1182

Other funds holding PCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return

Bartlett & Co's PCRX Position: Q1 2023 in Review

Bartlett & Co sold out of Pacira BioSciences (PCRX) in Q1 2023, closing a stake of 32 shares — an estimated $1K sold.

Bartlett & Co first reported a position in PCRX in Q2 2022 and held it in 3 quarters. The position peaked at $2K in Q3 2022. 267 funds tracked by Wall St. Rank hold PCRX as of Q1 2023.

  • Bartlett & Co reported no remaining Pacira BioSciences position as of Q1 2023 after selling out during the quarter.
  • Bartlett & Co sold 32 Pacira BioSciences shares in Q1 2023, an estimated $1K.
  • Bartlett & Co first reported a position in Pacira BioSciences in Q2 2022 and held it in 3 quarters.
  • Bartlett & Co's Pacira BioSciences position peaked at $2K in Q3 2022.
  • 267 funds tracked by Wall St. Rank held Pacira BioSciences as of Q1 2023.

Based on Bartlett & Co's 13F filing for Q1 2023, filed 6 Apr 2023.